WhatsApp used in research, but is this ethical?

By HEOR Staff Writer

March 15, 2023

Globally, WhatsApp Messenger has emerged as one of the world’s fastest-growing MIM applications. It has particularly high penetration rates in India, Indonesia, Malaysia, Brazil and South Africa.

The sub-Saharan African region is characterized by mixed migration flows and multiple health challenges, due to the inequalities experienced in access to healthcare disproportionately affect many groups including migrants and mobile populations. Given the existing structural factors impeding access to healthcare, coupled with high rates of mobile telephone use across the sub-Saharan African region; mobile phones are consistently recognized as having great potential for improving access to healthcare in this context.

WhatsApp was largely used in one of two ways for health research; to send hyperlinks to online surveys, or to deliver and evaluate, either an intervention designed for healthcare users or a communication programme for healthcare providers.

Challenges include efforts taken to ensure privacy, confidentiality and anonymity when using WhatsApp as a data collection tool; significant gender divide in access to mobile phones, with men being far more likely to have access to a device than women; features in WhatsApp that could potentially allow some encrypted messages to be read by unintended recipients, compounding the possible breaches of WhatsApp data.

Reference url

Recent Posts

clinical trial monitoring
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

By HEOR Staff Writer

May 22, 2026

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decisi...
Novartis oncology advancements
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...
EUDAMED Implementation 2026
EUDAMED Implementation 2026: Key Changes and National Adaptations
The EUDAMED Implementation 2026 will require mandatory use of four key modules in the European database on medical devices from 28 May 2026. These cover registration of economic operators, device registration via UDI, notified bodies and certificates, plus market surveillance, following earlier v...